Printer-friendly versionWoodcliff Lake, NJ, February 20, 2014 – Par Pharmaceutical Companies, Inc. today announced that Antonio R. Pera has been named chief commercial officer. Following its acquisition of JHP Pharmaceuticals, Mr. Pera has been chosen to lead Par’s newly-integrated sales and marketing organization. In this capacity, he will be instrumental in managing Par’s relationships with its major trade partners.
Mr. Pera joins Par from JHP where he served as senior vice president, commercial operations. He has more than 30 years’ experience in the pharmaceutical industry, including manufacturer and wholesaler, as well as generic and branded. Prior to joining JHP, Mr. Pera was senior vice president, supply chain management at AmerisourceBergen Corporation (ABC). While at ABC, he served as a corporate officer and led the procurement function for a Fortune 25 corporation with sales of more than $80 billion. Prior to ABC, his experience includes senior management positions at several leading generic pharmaceutical companies and he began his career in 1980 as a sales representative for Baxter Travenol Laboratories, Inc.
“Tony has enjoyed a distinguished career in the pharmaceutical industry and we are very pleased to have him join the Par team,” said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies. “He has a demonstrated expertise in the marketing, sales and distribution of generic drugs. We look forward to the leadership Tony will provide our commercial organization and the many contributions he will make to our company.”
Mr. Pera earned an MBA from DePaul University in 1984 and a B.S. in business administration from the University of Illinois, Champaign-Urbana in 1979.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary’s two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.